title: Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture.
abstract: Neuroprotection is the primary concern in patients with newly diagnosed Parkinson's disease. The D2/weak D1 dopamine agonist cabergoline elicits neuroprotection by antioxidation and scavenging free radicals, and may protect neurons by up-regulating endogenous neurotrophic factors synthesis in the brain. In primary cultured mouse astrocytes, cabergoline 37 micromol/l immediately elevated concentrations of nerve growth factor, brain-derived neurotrophic factor, and glial cell line-derived neurotrophic factor (GDNF) in culture medium, reaching 9.9-, 2.6- and 30-fold, respectively, of control levels at 16 h. Relative mRNA levels were 3.0-, 1.5- and 1.9-fold, respectively, of controls at 3 h. These effects may be mediated partly by the dopamine D2 receptor. Cabergoline may be a good candidate for an inducer of GDNF, which may have neuroprotective and neurorestorative properties in dopaminergic nigral neurons.
authors.affiliation: Clinical Research Center, Utano National Hospital, Kyoto, Japan.
authors.forename: Kiyoe
authors.initials: K
authors.lastname: Ohta
authors.forename: Aya
authors.initials: A
authors.lastname: Fujinami
authors.forename: Sadako
authors.initials: S
authors.lastname: Kuno
authors.forename: Asuka
authors.initials: A
authors.lastname: Sakakimoto
authors.forename: Hidehito
authors.initials: H
authors.lastname: Matsui
authors.forename: Yuji
authors.initials: Y
authors.lastname: Kawahara
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Ohta
mesh_terms: D000818:Animals; D001253:Astrocytes / Q000378:metabolism*; D019208:Brain-Derived Neurotrophic Factor / Q000096:biosynthesis* / Q000378:metabolism; D000077465:Cabergoline; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D004873:Ergolines / Q000008:administration & dosage / Q000494:pharmacology*; D051100:Glial Cell Line-Derived Neurotrophic Factor; D051379:Mice; D008813:Mice, Inbred ICR; D020932:Nerve Growth Factor / Q000096:biosynthesis* / Q000378:metabolism; D009414:Nerve Growth Factors / Q000096:biosynthesis* / Q000378:metabolism; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D017447:Receptors, Dopamine D1 / Q000819:agonists; D017448:Receptors, Dopamine D2 / Q000819:agonists; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D019208:Brain-Derived Neurotrophic Factor; D004873:Ergolines; C495040:Gdnf protein, mouse; D051100:Glial Cell Line-Derived Neurotrophic Factor; D009414:Nerve Growth Factors; D018696:Neuroprotective Agents; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D020932:Nerve Growth Factor; D000077465:Cabergoline